NASDAQ : LENZ

LENZ Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 3.05 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 95.83M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Details

NameLENZ Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees40
Founded2019
Ipo Date2021-06-25
CeoEvert Schimmelpennink
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price17.00
IsinUS52635N1037
Cusip52635N103
Cik1815776
Sic2836
Stock TypeCommon Stock

Key executives

NameTitle
Evert B. SchimmelpenninkPresident, Chief Executive Officer, Secretary and Director
James W. McCollumCo-Founder and Director
Shawn OlssonChief Commercial Officer
Marc G. Odrich M.D.Chief Medical Officer
Domenick PorfidiaVice President of Sales
David ChoromanskiVice President of Marketing
Melissa RosnessSenior Vice President of Manufacturing Operations
Kris GambelinSenior Vice President of Regulatory and Clincal Operations

Contact

Address201 Lomas Santa Fe Drive, Suite 300, Solana Beach, California 92075, United States
Phone858 925 7000
Websitehttps://www.lenz-tx.com